ESTRELLA IMMUNOPHARMA, INC. Increase (Decrease) in Accounts Payable, Related Parties
ESTRELLA IMMUNOPHARMA, INC. (ESLA) reported Increase (Decrease) in Accounts Payable, Related Parties of -$546.55 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties · last filed 2026-08-13
- ESTRELLA IMMUNOPHARMA, INC. increase (decrease) in accounts payable, related parties for the quarter ending 2026-06-30 was -$6.71K.
- ESTRELLA IMMUNOPHARMA, INC. increase (decrease) in accounts payable, related parties for the quarter ending 2026-03-31 was -$539.83K, a 5750.94% decline year-over-year.
- ESTRELLA IMMUNOPHARMA, INC. increase (decrease) in accounts payable, related parties for the quarter ending 2025-12-31 was $549.15K.
- ESTRELLA IMMUNOPHARMA, INC. increase (decrease) in accounts payable, related parties for the quarter ending 2025-09-30 was -$2.52K, a 150.46% decline year-over-year.
- ESTRELLA IMMUNOPHARMA, INC. increase (decrease) in accounts payable, related parties for fiscal 2025 was $550.35K.
- ESTRELLA IMMUNOPHARMA, INC. increase (decrease) in accounts payable, related parties for fiscal 2024 was -$9.33M, a 211.27% decline from fiscal 2023.
- ESTRELLA IMMUNOPHARMA, INC. increase (decrease) in accounts payable, related parties for fiscal 2023 was $8.39M.
| Period end | Increase (Decrease) in Accounts Payable, Related Parties 3 month | Increase (Decrease) in Accounts Payable, Related Parties 6 month | Increase (Decrease) in Accounts Payable, Related Parties 9 month | Increase (Decrease) in Accounts Payable, Related Parties 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$6.71K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$546.55K 10-Q · filed 2026-08-13 | $2.60K derived: sum of 3 quarters · filed 2026-08-13 | $78.00 derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$539.83K 10-Q · filed 2026-05-18 | $9.32K derived: sum of 2 quarters · filed 2026-05-18 | $6.79K derived: sum of 3 quarters · filed 2026-05-18 | $959.00 derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $549.15K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $546.63K derived: sum of 2 quarters · filed 2026-03-18 | $540.79K derived: sum of 3 quarters · filed 2026-08-13 | $550.35K 10-K · filed 2026-03-18 |
| 2025-09-30 | -$2.52K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$8.36K derived: sum of 2 quarters · filed 2026-08-13 | $1.20K 10-Q · filed 2025-11-12 | $631.00 derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$5.83K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $3.72K 10-Q · filed 2026-08-13 | $3.15K derived: sum of 3 quarters · filed 2026-08-13 | $8.15K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $9.55K 10-Q · filed 2026-05-18 | $8.99K derived: sum of 2 quarters · filed 2026-05-18 | $13.99K derived: sum of 3 quarters · filed 2026-05-18 | $13.99K derived: sum of 4 quarters · filed 2026-05-18 |
| 2024-12-31 | -$565.00 derived: 10-K 6 month − 10-Q 3 month · filed 2026-03-18 | $4.43K 10-K · filed 2026-03-18 | $4.43K derived: sum of 3 quarters · filed 2026-03-18 | -$72.64K derived: sum of 4 quarters · filed 2026-03-18 |
| 2024-09-30 | $5.00K 10-Q · filed 2024-11-14 | $5.00K derived: sum of 2 quarters · filed 2025-08-12 | -$72.08K 10-Q · filed 2025-11-12 | -$9.33M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$77.08K 10-Q · filed 2025-08-12 | -$9.34M derived: sum of 3 quarters · filed 2025-08-12 | -$9.33M 10-KT · filed 2025-03-25 |
| 2024-03-31 | -$77.08K 10-Q · filed 2025-05-14 | -$9.34M derived: sum of 2 quarters · filed 2025-05-14 | -$9.33M 10-Q · filed 2024-05-15 | -$6.87M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$9.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-14 | -$9.26M 10-Q · filed 2024-02-14 | -$6.79M derived: sum of 3 quarters · filed 2024-11-14 | -$4.23M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-09-30 | $4.50K 10-Q · filed 2024-11-14 | $2.47M derived: sum of 2 quarters · filed 2024-11-14 | $5.03M derived: sum of 3 quarters · filed 2024-11-14 | $7.61M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $2.46M derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-27 | $5.02M derived: sum of 2 quarters · filed 2024-09-27 | $7.61M derived: sum of 3 quarters · filed 2024-09-27 | $8.39M 10-K · filed 2024-09-27 |
| 2023-03-31 | $2.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-15 | $5.14M derived: sum of 2 quarters · filed 2024-05-15 | $5.93M 10-Q · filed 2024-05-15 | |
| 2022-12-31 | $2.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-14 | $3.37M 10-Q · filed 2024-02-14 | ||
| 2022-09-30 | $782.21K 10-Q · filed 2023-11-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |